SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
T-ALL is a neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells with scant cytoplasm, moderately condensed to dispersed chromatin and inconspicuous nucleoli, involving bone marrow and blood.
Most ALL patients present with widespread lymph node involvement as well as peripheral blood involvement. The number of circulating neoplastic cells does not correlate with the degree of bone marrow involvement, suggesting that circulating cells are recruited from other organs such as the skin. In fact, the skin is the most common extra-lymphatic site of involvement.
The disease is usually systemic, involving the spleen and extranodal sites including skin, lung, liver, GI tract and CNS.
Several clinical variants have been identified: 1. Acute 2. Chronic 3. Lymphomatous 4. Smoldering ATLL
Patients often present with a high leukocyte count and often a large mediastinal mass or other tissue mass.